TetraLogic Pharmaceuticals Corp. (Nasdaq: TLOG) temporarily halted enrollment in a chronic hepatitis B trial sending the stock price plummeting $1.38 to close at $2.40.
TetraLogic halts study enrollment
May 06, 2015 at 17:11 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|